Ein Unternehmen der RHÖN-KLINIKUM AG

Klinische Studien

A Phase II single arm clinical trial of a Tailore ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma

Astra Zeneca Potomac
A phase III randomized, open-label, multi-center, global study of Durvalumab und Bacillus Calmette-Guerin (BCG) administered as combination therapy versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer patients

BBI CanStem 303C
A phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in adult patients with previously treated metastastic colorectal cancer (CRC)

BMS CA209-274
A phase 3 randomized, double-blind, multi-center study of adjuvant Nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma

BMS CA209-577
A randomized, multicenter, double-blind, phase III study of Nivolumab or placebo in subjects with resected lower esophageal, or gastroesophageal junction cancer

A phase 3b randomized clinical trial of Nivolumab alone, Nivolumab in combination with Ipilimumab, or an investigator’s choice chemotherapy in participants with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW)

BMS CA 224-060-0016
A randomized, open-label, phase II clinical trial of Relatlimab (anti-LAG-3) plus Nivolumab in combination with chemotherapy versus Nivolumab in combination with chemotherapy as first-line treatment in patients with gastric or gastroesohageal junction adenocarcinoma

A randomized trial comparing the ELUVIA™ drug-eluting stent versus bare Metal self-expanding nitlNol stEnts in the treatmeNt of superficial femoral and/or proximal popliteal arTeries

CONCEPT - Uni Tübingen
A clinical phase II, multicenter, open-label study evaluating induction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in primary diagnosed high-risk multiple myeloma patients

Delcath FOCUS
A randomized, controlled, phase 3 study to evaluate the efficacy, safety and pharmacokinetics of Melphalan/HDS Treatment in patients with hepatic-dominant ocular melanoma

A prospective, randomized, controlled, phase II study of the AIO Pancreatic Cancer Group

Gastro NIFE
NaI-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer – An open label, non-comparative, randomized, multicenter phase II trial

Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapywith STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs

Isofol Medical AB, ISO-CC-007, AGENT
 randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

A prospective, randomized, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET)

LSK AM-301
A prospective, randomized, double-blinded, placebo-controlled, multinational, multicenter, parallel-group, phase III study to evaluate the efficacy and safety of Apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer (GC)

Merck Sharp & Dohme (MSD) MK3475-630
A phase 3, randomized, double-blind, placebo-controlled study to evaluate Pembrolizumab versus placebo as adjuvant therapy following surgery and radiation in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) (KEYNOTE-630)

MR-COPD II - Uniklinikum Heidelberg
Imaging disease progression in COPD (MR-COPD II)

MSD MK7902-011
A phase 3, randomized, double-blind study to compare the efficacy and safety of Pembrolizumab (MK-3475) in combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and placebo as first line treatment for locally advanced or metastatic urothelial carcinoma in Cisplatin-ineligible participants whose tumors express PD-L1, and in participants ineligible for any platinum-containing chemotherapy regardless of PD-L1 expression (LEAP-011)

Novartis COMB157G2301
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis

Novartis COMB157G2399
An open-label, single arm, multi-center trial, enrolling patients that have participated in an RMS study to evaluate long-term safety, tolerability and effectiveness

Novartis CPDR001
An open-label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal GI) or thoracic origin who have progressed on prior treatment

Pharmacept HEPASTAR
HEPAtocellular carcinoma: Management with transarterial chemoembolization with degradable STARch microspheres (DSM-TACE)

PQ Bypass Stent Graft System long segment lesion peripheral artery revascularization feasibility study

Co-clinical establishment of a prospective clinical database and biobank of fine needle biopsy material from metastases of patients with stage IV PDAC under real-life conditions for the clinical validation of the two-tiered PREDICT-PACA approach to precision medicine.

A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive welldifferentiated metastatic pancreatic neuroendocrine tumors

Roche MA30005
An open-label study to evaluate the efficacy and safety of Ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

Roche MA30143
An open-label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis

Roche MO297872, Ipsos
A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of Atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy

Sanofi BOREAS, EFC15804
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Sanofi EFC15805, NOTUS
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Sojournix SJX-653-006
A phase 2, prospective, randomized, double-blind, placebo-controlled clinical study to assess the efficacy, safety, tolerability and pharmacokinetics of SJX-653 in postmenopausal women with moderate to severe vasomotor symptoms

A phase 2, randomized, open-label study of Nivolumab combined with Ipilimumab versus standard of care in subjects with previously untreated and advanced (unresectable or metastastic) non-clear cell renal cell carcinoma